Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(8):1017–1020. doi: 10.1038/bjc.1997.501

Vitamin D receptors and anti-proliferative effects of vitamin D derivatives in human pancreatic carcinoma cells in vivo and in vitro.

K W Colston 1, S Y James 1, E A Ofori-Kuragu 1, L Binderup 1, A G Grant 1
PMCID: PMC2228083  PMID: 9376260

Abstract

The GER human pancreatic carcinoma cell line possesses receptors for 1,25-dihydroxyvitamin D3. We report that the vitamin D analogue EB 1089 inhibits the growth of these cells in vitro and when grown as tumour xenografts in immunodeficient mice. Tumour-bearing mice were given EB 1089 at a dose of 5 microg kg(-1) body weight i.p. thrice weekly for 4-6 weeks. Tumour growth was significantly inhibited in treated animals compared with controls in the absence of hypercalcaemia. These findings may have therapeutic implications in pancreatic cancer.

Full text

PDF
1017

Images in this article

1018Figure 1
on p.1018

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe J., Nakano T., Nishii Y., Matsumoto T., Ogata E., Ikeda K. A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology. 1991 Aug;129(2):832–837. doi: 10.1210/endo-129-2-832. [DOI] [PubMed] [Google Scholar]
  2. Andrén-Sandberg A., Bäckman P. L. Sex hormones and pancreatic cancer. Baillieres Clin Gastroenterol. 1990 Dec;4(4):941–952. doi: 10.1016/0950-3528(90)90028-f. [DOI] [PubMed] [Google Scholar]
  3. Bakkevold K. E., Pettersen A., Arnesjø B., Espehaug B. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg. 1990 Jul;77(7):725–730. doi: 10.1002/bjs.1800770704. [DOI] [PubMed] [Google Scholar]
  4. Bold R. J., Ishizuka J., Townsend C. M., Jr, Thompson J. C. All-trans-retinoic acid inhibits growth of human pancreatic cancer cell lines. Pancreas. 1996 Mar;12(2):189–195. doi: 10.1097/00006676-199603000-00014. [DOI] [PubMed] [Google Scholar]
  5. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  6. Colston K. W., Chander S. K., Mackay A. G., Coombes R. C. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol. 1992 Aug 18;44(4):693–702. doi: 10.1016/0006-2952(92)90405-8. [DOI] [PubMed] [Google Scholar]
  7. Colston K. W., Mackay A. G., James S. Y., Binderup L., Chander S., Coombes R. C. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol. 1992 Dec 15;44(12):2273–2280. doi: 10.1016/0006-2952(92)90669-a. [DOI] [PubMed] [Google Scholar]
  8. Colston K., Colston M. J., Feldman D. 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology. 1981 Mar;108(3):1083–1086. doi: 10.1210/endo-108-3-1083. [DOI] [PubMed] [Google Scholar]
  9. Colston K., Wilkinson J. R., Coombes R. C. 1,25-Dihydroxyvitamin D3 binding in estrogen-responsive rat breast tumor. Endocrinology. 1986 Jul;119(1):397–403. doi: 10.1210/endo-119-1-397. [DOI] [PubMed] [Google Scholar]
  10. Dokoh S., Donaldson C. A., Haussler M. R. Influence of 1,25-dihydroxyvitamin D3 on cultured osteogenic sarcoma cells: correlation with the 1,25-dihydroxyvitamin D3 receptor. Cancer Res. 1984 May;44(5):2103–2109. [PubMed] [Google Scholar]
  11. Frampton R. J., Omond S. A., Eisman J. A. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. Cancer Res. 1983 Sep;43(9):4443–4447. [PubMed] [Google Scholar]
  12. Grant A. G., Duke D., Hermon-Taylor J. Establishment and characterization of primary human pancreatic carcinoma in continuous cell culture and in nude mice. Br J Cancer. 1979 Feb;39(2):143–151. doi: 10.1038/bjc.1979.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Grant A. G., Flomen R. M., Tizard M. L., Grant D. A. Differential screening of a human pancreatic adenocarcinoma lambda gt11 expression library has identified increased transcription of elongation factor EF-1 alpha in tumour cells. Int J Cancer. 1992 Mar 12;50(5):740–745. doi: 10.1002/ijc.2910500513. [DOI] [PubMed] [Google Scholar]
  14. James S. Y., Mackay A. G., Binderup L., Colston K. W. Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol. 1994 Jun;141(3):555–563. doi: 10.1677/joe.0.1410555. [DOI] [PubMed] [Google Scholar]
  15. James S. Y., Mackay A. G., Colston K. W. Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. J Mol Endocrinol. 1995 Jun;14(3):391–394. doi: 10.1677/jme.0.0140391. [DOI] [PubMed] [Google Scholar]
  16. Kuerbitz S. J., Plunkett B. S., Walsh W. V., Kastan M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7491–7495. doi: 10.1073/pnas.89.16.7491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mathiasen I. S., Colston K. W., Binderup L. EB 1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Mol Biol. 1993 Sep;46(3):365–371. doi: 10.1016/0960-0760(93)90226-m. [DOI] [PubMed] [Google Scholar]
  18. McGuire W. L., DeLaGarza M. Improved sensitivity in the measurement of estrogen receptor in human breast cancer. J Clin Endocrinol Metab. 1973 Dec;37(6):986–989. doi: 10.1210/jcem-37-6-986. [DOI] [PubMed] [Google Scholar]
  19. Poston G. J., Townsend C. M., Jr, Rajaraman S., Thompson J. C., Singh P. Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas. 1990 Mar;5(2):151–157. doi: 10.1097/00006676-199003000-00005. [DOI] [PubMed] [Google Scholar]
  20. Taylor O. M., Benson E. A., McMahon M. J. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group. Br J Surg. 1993 Mar;80(3):384–386. doi: 10.1002/bjs.1800800341. [DOI] [PubMed] [Google Scholar]
  21. Wong A., Chan A. Survival benefit of tamoxifen therapy in adenocarcinoma of pancreas. A case-control study. Cancer. 1993 Apr 1;71(7):2200–2203. doi: 10.1002/1097-0142(19930401)71:7<2200::aid-cncr2820710706>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  22. Wosikowski K., Küng W., Hasmann M., Löser R., Eppenberger U. Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells. Int J Cancer. 1993 Jan 21;53(2):290–297. doi: 10.1002/ijc.2910530220. [DOI] [PubMed] [Google Scholar]
  23. Zugmaier G., Jäger R., Grage B., Gottardis M. M., Havemann K., Knabbe C. Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br J Cancer. 1996 Jun;73(11):1341–1346. doi: 10.1038/bjc.1996.256. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES